201 related articles for article (PubMed ID: 1649252)
41. Depletion of norepinephrine in mouse heart by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mimicked by 1-methyl-4-phenylpyridinium (MPP+) and not blocked by deprenyl.
Fuller RW; Hemrick-Luecke SK
Life Sci; 1986 Nov; 39(18):1645-50. PubMed ID: 3095601
[TBL] [Abstract][Full Text] [Related]
42. Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in rodents.
Sundström E; Samuelsson EB
Pharmacol Toxicol; 1997 Nov; 81(5):226-31. PubMed ID: 9396088
[TBL] [Abstract][Full Text] [Related]
43. Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.
Shimazu S; Takahata K; Tamashiro A; Yoneda F; Iida Y; Saji H
J Neural Transm (Vienna); 2003 Aug; 110(8):871-83. PubMed ID: 12898343
[TBL] [Abstract][Full Text] [Related]
44. Sustained depletion of cortical and hippocampal serotonin and norepinephrine but not striatal dopamine by 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH2-MPTP): a comparative study with 2'-CH3-MPTP and MPTP.
Andrews AM; Murphy DL
J Neurochem; 1993 Mar; 60(3):1167-70. PubMed ID: 8094744
[TBL] [Abstract][Full Text] [Related]
45. Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice.
Kato H; Kurosaki R; Oki C; Araki T
Brain Res; 2004 Dec; 1030(1):66-73. PubMed ID: 15567338
[TBL] [Abstract][Full Text] [Related]
46. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha.
Sriram K; Matheson JM; Benkovic SA; Miller DB; Luster MI; O'Callaghan JP
FASEB J; 2006 Apr; 20(6):670-82. PubMed ID: 16581975
[TBL] [Abstract][Full Text] [Related]
47. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine pretreatment attenuates methamphetamine-induced dopamine toxicity.
Kita T; Saraya T; Konishi N; Matsunari Y; Shimada K; Nakamura M; O'Hara K; Wagner GC; Nakashima T
Pharmacol Toxicol; 2003 Feb; 92(2):71-80. PubMed ID: 12747576
[TBL] [Abstract][Full Text] [Related]
48. Metabolism of [14C]MPTP in mouse and monkey implicates MPP+, and not bound metabolites, as the operative neurotoxin.
Yang SC; Johannessen JN; Markey SP
Chem Res Toxicol; 1988; 1(4):228-33. PubMed ID: 2979736
[TBL] [Abstract][Full Text] [Related]
49. Comparison of the effects of two 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs, 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine and 1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine, on monoamine oxidase in vitro and on dopamine in mouse brain.
Fuller RW; Robertson DW; Hemrick-Luecke SK
J Pharmacol Exp Ther; 1987 Feb; 240(2):415-20. PubMed ID: 3100775
[TBL] [Abstract][Full Text] [Related]
50. Neurotoxicity of MPTP and uptake of MPPT into dopamine and norepinephrine neurons in mice.
Lee EH; Lu KT
Adv Exp Med Biol; 1995; 363():29-46. PubMed ID: 7618528
[No Abstract] [Full Text] [Related]
51. A model of chronic neurotoxicity: long-term retention of the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) within catecholaminergic neurons.
Johannessen JN
Neurotoxicology; 1991; 12(2):285-302. PubMed ID: 1956587
[TBL] [Abstract][Full Text] [Related]
52. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice.
Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
J Pharmacol Exp Ther; 1991 May; 257(2):691-7. PubMed ID: 2033514
[TBL] [Abstract][Full Text] [Related]
53. Kinetics of [3H]MPP+ uptake in dopaminergic neurons of mouse: regional effects of MPTP neurotoxicity.
Sershen H; Mason MF; Debler EA; Lajtha A
Eur J Pharmacol; 1986 Jul; 126(3):337-9. PubMed ID: 3489627
[TBL] [Abstract][Full Text] [Related]
54. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
[TBL] [Abstract][Full Text] [Related]
55. Behavioral and biochemical changes following acute administration of MPTP and MPP+.
Tadano T; Satoh N; Sakuma I; Matsumura T; Kisara K; Arai Y; Kinemuchi H
Life Sci; 1987 Mar; 40(13):1309-18. PubMed ID: 2436017
[TBL] [Abstract][Full Text] [Related]
56. The neurotoxin MPTP does not affect striatal superoxide dismutase activity in mice.
Pikarsky E; Melamed E; Rosenthal J; Uzzan A; Michowiz SD
Neurosci Lett; 1987 Dec; 82(3):327-31. PubMed ID: 2827077
[TBL] [Abstract][Full Text] [Related]
57. Uptake inhibition protects nigro-striatal dopamine neurons from the neurotoxicity of 1-methyl-4-phenylpyridine (MPP+) in mice.
Sundström E; Goldstein M; Jonsson G
Eur J Pharmacol; 1986 Nov; 131(2-3):289-92. PubMed ID: 3493159
[TBL] [Abstract][Full Text] [Related]
58. Serotonergic conversion of MPTP and dopaminergic accumulation of MPP+.
Shen RS; Abell CW; Gessner W; Brossi A
FEBS Lett; 1985 Sep; 189(2):225-30. PubMed ID: 3876242
[TBL] [Abstract][Full Text] [Related]
59. MPTP- and MPP(+)-induced effects on body temperature exhibit age- and strain-dependence in mice.
Freyaldenhoven TE; Ali SF; Hart RW
Brain Res; 1995 Aug; 688(1-2):161-70. PubMed ID: 8542303
[TBL] [Abstract][Full Text] [Related]
60. Differential effects of deprenyl and MPTP on catecholamines and activity in BALB/c mice.
Chia LG; Liu SP; Lee EH
Neuroreport; 1992 Sep; 3(9):777-80. PubMed ID: 1421136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
